Jinggangshan University

Zn-I2 batteries have emerged as promising next-generation energy storage systems owing to their inherent safety, environmental compatibility, rapid reaction kinetics, and small voltage hysteresis. Nevertheless, two critical challenges, i.e., zinc dendrite growth and polyiodide shuttle effect, severely impede their commercial viability. To conquer these limitations, this study develops a multifunctional separator fabricated from straw-derived carboxylated nanocellulose, with its negative charge density further reinforced by anionic polyacrylamide incorporation. This modification simultaneously improves the separator’s mechanical properties, ionic conductivity, and Zn2+ ion transfer number. Remarkably, despite its ultrathin 20 μm profile, the engineered separator demonstrates exceptional dendrite suppression and parasitic reaction inhibition, enabling Zn//Zn symmetric cells to achieve impressive cycle life (> 1800 h at 2 mA cm−2/2 mAh cm−2) while maintaining robust performance even at ultrahigh areal capacities (25 mAh cm−2). Additionally, the separator’s anionic characteristic effectively blocks polyiodide migration through electrostatic repulsion, yielding Zn-I2 batteries with outstanding rate capability (120.7 mAh g−1 at 5 A g−1) and excellent cyclability (94.2% capacity retention after 10,000 cycles). And superior cycling stability can still be achieved under zinc-deficient condition and pouch cell configuration. This work establishes a new paradigm for designing high-performance zinc-based energy storage systems through rational separator engineering.

Amyloid deposition of human islet amyloid polypeptide (hIAPP) is closely linked to the pathogenesis and progression of type 2 diabetes mellitus (T2DM). Developing effective inhibitors to suppress hIAPP aggregation holds significant therapeutic potential for the prevention and treatment of T2DM. Recent researches indicate that both heme and lithospermic acid (LPA) can inhibit hIAPP aggregation. However, heme is prone to induce protein damage under oxidative stress, while LPA exhibits limited inhibitory efficacy despite its antioxidant properties. To overcome these limitations, we aimed to develop a dual-component inhibitor comprising heme and LPA. thioflavin T (ThT) fluorescence, transmission electron microscopy (TEM), circular dichroism (CD) and gel electrophoresis were combined to observe the inhibitory efficacy of heme-LPA co-formulation on hIAPP aggregation. The results demonstrate that LPA and heme can synergistically inhibit hIAPP aggregation. The inhibitory effect of heme-LPA co-formulation on hIAPP aggregation is significantly stronger than that of either component alone. The heme-LPA not only prevents the complete conversion of hIAPP into β-sheet fibrillar structures but also maintains its active monomeric conformation for extended periods. Furthermore, peroxidase activity assays revealed that the presence of LPA significantly reduces the peroxidase activity of heme in a concentration-dependent manner and attenuates peptide nitration damage under H₂O₂-NO₂^- oxidative stress. At a heme-to-LPA ratio of 1:4, peptide nitration bands were virtually undetectable. These findings indicate that the dual-component inhibitor heme-LPA represents an efficient and safe strategy for inhibiting hIAPP aggregation. This research provides an important avenue for developing novel anti-hIAPP aggregation inhibitors for the prevention and treatment of T2DM.

Current antithrombotic therapies face dual constraints of bleeding complications and monitoring requirements. Although natural hirudin provides targeted thrombin inhibition, its clinical adoption is hindered by sourcing limitations. This study developed a recombinant hirudin variant HMg (rHMg) with enhanced anticoagulant activity through genetic engineering and established cost-effective large-scale production methods. The synthesised HMg gene was expressed in E. coli BL21 via a pET vector plasmid, followed by nickel-affinity purification. Systematic evaluations demonstrated rHMg's antithrombin activity of 9573 ATU/mg, dose-dependent prolongation of APTT/PT/TT. It has superior thrombin inhibition with the IC₅₀ and K_i values were 2.8 and 0.323 nM respectively compared to FDA approved drug bivalirudin (p < 0.001). The high-yield prokaryotic expression of rHMg with enhanced anticoagulant efficacy provides a novel strategy for developing affordable antithrombotic drugs, showing significant potential for cardiovascular disease management.